Bloodstream Infection Testing Market - Size, Industry Share, Growth Trends and Forecasts (2023 - 2031)

Bloodstream Infection Testing Market Dynamics - (DRO) :

Key Drivers :

Increasing incidences of bloodstream infections across the globe.

Bloodstream infections are the leading cause of death worldwide. This drives the demand for accurate and advanced testing solutions for bloodstream infections. Healthcare-associated infections, intravascular catheter-associated infections, and antimicrobial resistance harm the patients. Additionally, using invasive medical procedures and devices in COVID-19 patients has increased the risk of healthcare-associated bloodstream infections. These infections can evolve into serious deep-seated infectious complications such as bacterial endocarditis, lung abscesses, and infectious embolic events to major organs such as the brain and kidneys. For instance, according to the World Health Organization in June 2023, Bloodstream infections due to a range of resistant pathogens that are mostly associated with health care, were found to be the second most frequent cause of the global burdens attributable to and associated with AMR in 2019, causing almost 1.5 million deaths around the world. The analysis of market trends concludes that the growing incidences of bloodstream infections across the globe are driving the bloodstream infection testing market demand globally.

Growing awareness of the importance of early detection and treatment of bloodstream infection

Bloodstream infections (BSIs) are serious medical conditions caused by the presence of bacteria or fungi in the bloodstream. Bloodstream infections can lead to several complications, including sepsis, septic shock, and death. Early detection and treatment of BSIs are crucial for improving patient outcomes and reducing mortality. There is a significant rise in the number of blood infections across the globe leading to various lethal complications among the population. For instance, according to the report by HIV.gov, a US government website that provides information and resources on HIV and AIDS in July 2023, approximately 86% of people with HIV globally knew their HIV status in 2022. The remaining 14% (about 5.5 million people) did not know they had HIV and still needed access to HIV testing services. HIV testing is an essential gateway to HIV prevention, treatment, care, and support services. The global target for HIV status awareness is 95% by 2025. The analysis of market trends concludes that the growing awareness of the importance of early detection and treatment of BSIs is driving the adoption of newer and more sensitive BSI testing technologies. This is leading to an increase in the demand for BSI testing services and driving market proliferation.

Key Restraints :

High maintenance cost and prices of devices and consumables

The high cost of ownership and maintenance of devices is the restraining factor for the bloodstream infection testing market growth. Automated devices required for both conventional and advanced bloodstream infection tests such as PCR machines, and MALDI- TOF analyzers are equipped with several advanced features and functions. Additionally, these devices need special teams for their service, hence managing them is very expensive.

Furthermore, the high cost of instruments, consumables, and labor significantly affects end-user industries. Diagnostic laboratories and research industries require multiple such systems and hence capital cost increases ominously. On the other hand, research institutes run on limited funds, so they cannot afford such systems. Thus, all these factors contribute to the higher cost of bloodstream injection testing which is hampering the growth of the bloodstream infection testing market trends.

Future Opportunities :

Growing government initiatives for healthcare research and development activities

Extensive research activities have created ample space for the development and growth of the bloodstream infection testing market opportunities. Technological advancement such as next-generation sequencing of microbial cell-free DNA (mcfDNA-seq) is expected to emerge as a promising diagnostic method for bloodstream infection. Moreover, these techniques will help to develop sensitive, rapid, specific, and cost-efficient detection methods to decrease the negative impact of bloodstream infections for rapid antimicrobial susceptibility testing (AST) to enable the reduction of antibiotic therapy as early as possible. Since the COVID pandemic, several government initiatives have also supported the bloodstream infection testing market demand to reduce the rising cases of sepsis and antimicrobial resistance. For instance, In February 2020, in the United Kingdom, the National Institute for Health and Care Excellence (NICE) issued guidance recommending the use of rapid bloodstream infection testing in certain settings, such as emergency departments and intensive care units. The analysis of trends in the market concludes that the growing government initiatives for healthcare research and development activities are emerging as one of many bloodstream infection testing market opportunities that will drive market expansion across the globe over the forecast period.

By Product Type :

The product type of segmentation is categorized into consumables, instruments, and software. In 2022, the consumables segment accounted for the highest bloodstream infection testing market share. Consumable bloodstream infection testing refers to the use of disposable materials and reagents to detect bloodstream infections. These consumables are used in a variety of testing methods, including blood culture, nucleic acid testing (NAT), and mass spectrometry. Consumables are used in every bloodstream infection test, such as blood culture bottles, media, and reagents. Additionally, consumables are relatively inexpensive and have a short shelf life, which drives their demand across the globe.

Moreover, the instruments are expected to hold the highest CAGR over the forecast period. Instruments products in bloodstream infection testing are devices that are used to detect and identify bacteria and fungi in the bloodstream. These devices are becoming increasingly popular because they offer several advantages over traditional methods of testing, such as blood culture. Advancements in instruments such as automated blood culture systems and molecular diagnostics instruments are helping to reduce the turnaround time for testing. The superior performance characteristics of the products are creating lucrative growth prospects for the segment over the forecast period.

By Technology :

The technology segment is categorized into conventional, PCR methods, nucleic acid testing, mass spectroscopy, and POC testing. In 2022, the conventional segment accounted for the highest market share in the bloodstream infection testing market share. Conventional bloodstream infection (BSI) testing is the traditional method for detecting bacteria and fungi in the bloodstream. It involves collecting a blood sample and incubating it in a nutrient-rich broth for several days. If bacteria or fungi are present in the blood sample, they will grow in the broth and can be detected by a laboratory technician. The analysis of segment trends concludes that the growing awareness of the importance of early detection and treatment of bloodstream infections is driving market expansion across the globe.

Moreover, the POC testing is expected to hold the highest CAGR over the forecast period. Point-of-care (POC) testing refers to the use of small, portable devices to detect bloodstream infections at the patient's bedside. POC testing devices can be used to detect bacteria, fungi, and viruses in the bloodstream. POC tests produce results in minutes or hours, compared to days for traditional laboratory-based tests. This can lead to earlier diagnosis and treatment of bloodstream infections, which can improve patient outcomes. The faster turnaround time of POC testing is creating lucrative growth prospects for POC testing over the forecast period.

By End-User :

The end user segment is categorized into hospitals, diagnostic centers, research institutes, and others. In 2022, the hospitals segment accounted for the highest market share of 43.10% in the application segment. Hospitals are the primary setting where bloodstream infections are diagnosed and treated. Hospitals have the necessary infrastructure and resources to perform a variety of bloodstream infection tests, including blood culture, nucleic acid testing (NAT), and mass spectrometry. Assessment of market trends indicates that the increasing number of hospitals across the developing economies is driving the demand for bloodstream infection testing from the healthcare industry across the globe. For instance, according to the report by Investment Information and Credit Rating Agency, in August 2023, the hospital industry is expecting a robust revenue increase of 8-10% in FY24, with an operating profit margin of 22-23%. Thus, the growing need for the testing procedure from the healthcare industry is driving the bloodstream infection testing market growth.

Moreover, the diagnostic centers are expected to hold the highest CAGR over the forecast period. The need for bloodstream infection testing is growing from diagnostic centers due to the increasing requirement for outpatient infection testing. Diagnostic centers offer patients a convenient and affordable way to get tested for bloodstream infections. Growing government initiatives for the development of diagnostic centers are fueling the market growth. For instance, according to the report by the Government of the United Kingdom in May 2023, The government has committed USD 2.81 billion to launch up to 160 community diagnostic centers (CDCs) by March 2025. Analysis of bloodstream infection testing market trends concludes that the growing number of diagnostic centers is expected to drive segment growth across the globe.

By Region :

The regional segment includes North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

In 2022, North America accounted for the highest market share at 38.25% valued at USD 1,255.99 Million in 2022 and USD 1,307.85 Million in 2023, it is expected to reach USD 1,864.86 Million in 2031. In North America, the U.S. accounted for the highest market share of 63.10% in the base year 2022. The bloodstream infection testing market analysis concluded that the significant rise in bloodstream infections across the North American region is driving market proliferation across the region. For instance, According to the Centers for Disease Control and Prevention (CDC) in September 2021, at least 1.7 million adults in the U.S. develop sepsis each year which leads to 270,000 every year. Furthermore, according to the report by the National Institute of Health in November 2022, An estimated 250,000 bloodstream infections occur annually, and most are related to the presence of intravascular devices. In the United States, the CLABSI rate in intensive care units (ICU) is estimated to be 0.8 per 1000 central line days. Thus, the growing prevalence of blood infections in the North American region is driving the market expansion.

Furthermore, the Asia Pacific region is expected to witness significant growth over the forecast period, growing at a CAGR of 4.9% during 2023-2031. The analysis of regional trends concludes that the significant proliferation in healthcare infrastructure across the region across the region is increasing the need for bloodstream infection testing. For instance, according to a report by the National Institute of Health in May 2023, China's healthcare budget is gradually increasing. The ratio of health expenditures to GDP in 2021 was 6.5%. It was only 4.3% to 5.2% during the period from 2000 to 2010. The total national health expenditure in 2021 will be USD 1184.9 billion. Thus, the significant development of healthcare infrastructure is expected to drive market proliferation over the forecast period.

Top Key Players & Market Share Insights:

The bloodstream infection testing market is highly competitive, with several large players and numerous small and medium-sized enterprises. The major companies operating in the bloodstream infection testing industry have strong research and development capabilities and a strong presence in the market through their extensive product portfolios and distribution networks. Assessment of market trends indicates that the market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market through mergers, acquisitions, and partnerships. The key players in the market include-